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TauopathyThe energydemand and calciumbuffering requirements of the brain aremet by thehighnumberofmitochondria
in neurons and in these, especially at the synapses. Mitochondria are themajor producer of reactive oxygen spe-
cies (ROS); at the same time, they are damaged by ROS that are induced by abnormal protein aggregates that
characterize human neurodegenerative diseases such as Alzheimer's disease (AD). Because synaptic mitochon-
dria are long-lived, any damage exerted by these aggregates impacts severely on neuronal function. Here we
review how increased TAU, a deﬁning feature of AD and related tauopathies, impairs mitochondrial function
by following the principle: ‘March separate, strike together!’ In the presence of amyloid-β, TAU's toxicity
is augmented suggesting synergistic pathomechanisms. In order to restore mitochondrial functions in
neurodegeneration as a means of therapeutic intervention it will be important to integrate the various aspects
of dysfunction and get a handle on targeting distinct cell types and subcellular compartments. This article is
part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.
© 2013 Published by Elsevier B.V.1. Introduction
The family of microtubule-associated proteins (MAPs) comprises
three major classes of polypeptides: MAP1 (N250 kDa), MAP2
(~200 kDa), and TAU (50–70 kDa) [1,2]. MAP2 and TAU are expressed
in most neurons, where they localize to separate subcellular compart-
ments. While MAP2 is largely found in dendrites, TAU is concentrated
in axons [3]. In the roundworm Caenorhabditis elegans, protein with
TAU-like repeats (PTL-1) is the sole MAP homolog [4,5], allowing for
studies into shared functions of TAU and MAP2 [6]. In the human
brain, TAU exists as six isoforms that have either three or four
microtubule-binding domains. In the adult mouse brain, there are only
isoforms with four microtubule-binding domains expressed. TAU has
been localized to cell-types other than neurons such as astrocytes and
oligodendrocytes although under physiological conditions expression
levels are relatively low [7]. When TAU was discovered in 1975 [8],
the subsequent years focused mainly on its tissue distribution and the
role TAU has in microtubule assembly and stabilization. With the iden-
tiﬁcation of aggregates of TAU in the Alzheimer's disease (AD) brain, the
focus shifted to addressing pathological functions. Histopathologically,folded Proteins, Mitochondrial
a Research (CADR), Queensland
Lucia Campus, Brisbane, QLD
vier B.V.AD is characterized by reduced synaptic density, neuronal loss in select-
ed brain areas, as well as amyloid-β (Aβ)-containing plaques and neu-
roﬁbrillary tangles (NFTs). It is the ﬁlamentous core of NFTs that is
composed of highly phosphorylated forms of TAU [9,10].
1.1. TAU phosphorylation
What is the role of TAUphosphorylation in disease? TAU is a remark-
able protein inasmuch as it contains 80 serine and threonine residues
and 5 tyrosine residues that can be potentially phosphorylated [11]. In
the normal brain there are 2–3 mol of phosphate per mole of TAU. In
the AD brain, TAU is hyperphosphorylated to a stoichiometry of at
least three-fold greater than normal supporting the notion that phos-
phorylation is a critical step in the aggregation process [12]. Whether
phosphorylation at distinct sites is required or whether a generally ele-
vated level of phosphorylation is sufﬁcient is not known although the
latter possibility is suggested bywork inDrosophila [13].With the enter-
ing of a formulation of the TAU dye methylene blue (Rember) into clin-
ical trials a discussion has been initiated whether this putative drug is
truly an aggregation inhibitor [14] and more speciﬁcally whether TAU
in NFTs is massively phosphorylated (http://www.alzforum.org/new/
detail.asp?id=3410).
While one study claims that the ﬁlaments in the NFTs are entirely
composed of hyperphosphorylated TAU [15], another claims that
hyperphosphorylated TAU accounts for less than 10% of total TAU that
is moreover localized to the proteolytically susceptible fuzzy outer
coat of the ﬁlaments, and not to their structural core [16,17].
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The TAU ﬁeld has received a major boost with the identiﬁcation of
pathogenic mutations in the MAPT gene that encodes TAU in familial
cases (FTDP-17, frontotemporal dementia with Parkinsonism linked to
chromosome 17) of frontotemporal lobar degeneration (FTLD-TAU), a
disease that shares with AD the aggregation of TAU and NFT formation,
but lacks an overt Aβ pathology [18–20]. This enabled us and others to
express FTLD mutant forms of TAU in mice and thereby reproduce
TAU aggregation and NFT formation, and also to achieve a concomitant
behavioural impairment in transgenic mouse models [21]. One such
mouse strain generated in our laboratory is pR5 that expresses P301L
mutant TAU and because of the pattern of TAU aggregation in the
brain, displays amygdala- and hippocampus-dependent memory im-
pairments [22,23]. This and other mouse models were instrumental in
determining that manipulating phosphorylation by either inhibiting ki-
nases or activating phosphatases causes an amelioration of the TAU pa-
thology, including a restoration of behavioural impairments and
prevention of neuronal cell loss [24–26]. When TAU mutant pR5 mice
that progressively develop NFTs were crossed with phosphatase
(PP2A)-impaired mice, this caused 7-fold increased numbers of hippo-
campal neurons that speciﬁcally phosphorylated the pathological
Ser422 epitope of TAU, and 8-fold increased numbers of NFTs [27]. An-
other mouse strain generated by us expresses K369I mutant TAU and
because of a unique expression pattern that includes the substantia
nigra it is characterized by Parkinsonism [28]. Again, in these mice,
TAU is highly phosphorylated; however, different from the pR5 strain,
the 12E8 phospho-epitope Ser262/Ser356 is spared. Together this un-
derscores the importance of phosphorylation in disease. Importantly
and relevant to the topic of this article, TAU transgenic mouse models
have proven instrumental in highlighting mitochondrial dysfunction
as a central mechanism in neurodegeneration.
2. Mitochondrial dysfunction — cause or consequence
Mitochondria play a pivotal role in cell survival and death by regulat-
ing both energy metabolism and apoptotic pathways. They contribute
to many cellular processes including intracellular calcium homeostasis
and synaptic plasticity [29]. Maternally inherited, mitochondria are
compartmentalized organelles consisting of a matrix and two mem-
branes, an outer and an inner membrane with folded cristae, separated
by an intermembrane space. These organelles are the powerhouses of
all nucleated cells. They produce adenosine triphosphate (ATP) via the
combined efforts of the tricarboxylic cycle (TCA) and the oxidative
phosphorylation (OxPhos) system of the electron transport chain
(ETC). The respiratory chain comprises four biochemically linked
multi-subunit complexes I, II, III and IV, as well as two electron carriers,
ubiquinone/coenzyme Q and cytochrome C, that are localized at the
inner mitochondrial membrane (Fig. 1). By using the energy that is
stored in nutritional sources the respiratory chain generates a proton
gradient across the inner membrane to drive ATP synthesis via ATP
synthase (complex V), while at the same time transferring electrons
to oxygen and producing water [30]. Mitochondria are the major pro-
ducer of reactive oxygen species (ROS) and at the same time a target
of ROS toxicity [31]. The organelle has at its disposal a powerful quality
control system to dealwith these challenges:ﬁrstly intra-mitochondrial
proteases and molecular chaperones that maintain mitochondrial
proteostasis; secondly a dynamic network maintained by membrane
ﬁssion and fusion, a process termed mitochondrial dynamics, by
which damaged or defective mitochondrial components are isolated
and targeted for autophagy (mitophagy) [32]. Mitochondrial dynamics
cannot be discussed in isolation, as mitochondrial ﬁssion (i.e. biogene-
sis), fusion, motility/transport and turnover (by mitophagy) are highly
inter-dependent processes [33]. This is especially critical for highly
polarized cells such as neurons. The role of mitochondria in ageing
and in pathophysiological processes such as AD is constantly beingunravelled. Concomitant to ROSproduction an inefﬁcientmitochondrial
base excision repair (BER) machinery has been postulated, with oxida-
tive damage to mitochondrial DNA (mtDNA) being a determining
event that occurs during ageing [34].
2.1. Manipulating ﬁssion and fusion genes
The question arises whether any form of chronic oxidative stress-
associated event would at an early stage contribute to the synaptic ab-
normalities and, ultimately, selective neuronal degeneration that char-
acterizes AD, as a growing body of evidence would suggest [35]. The
bulk of AD cases are sporadic, and only a small fraction is caused by au-
tosomal dominant mutations. Regarding the role of mitochondrial dys-
function in AD one can envisage several scenarios. Firstly, oxidative
stress could be a down-stream consequence of another pathogenic
event; secondly, it could be the cause of neurodegeneration; thirdly, it
might accelerate and/or augment the damage elicited by TAU and/or
Aβ [31]. By manipulating mitochondrial in vivo genes with a role in fu-
sion and ﬁssion, a process discussed in more detail below, neither an
AD-like TAU nor an Aβ pathology has been encountered [36–41],
which would place mitochondrial dysfunction down-stream of TAU
and Aβ toxicity. However, as most mouse strains that lack ﬁssion or fu-
sion genes show early lethality it has not been possible to study conse-
quences for TAU and Aβ and in particular the role ageing has in such an
impairment.
2.2. Senescence-accelerated mice
In studying mitochondrial functions and age-related mitochondrial
decline, senescence-accelerated mouse strains such as SAMP8 (senes-
cence accelerated prone 8) are useful, as themice displaymany features
known to occur early in the pathogenesis of AD, such as increased oxi-
dative stress andmemory impairment [42]. Together with a series of re-
lated senescence-acceleratedmice, the SAMP8 strain was established in
the mid 1970s by conventional inbreeding of AKR/J-derived mice that
displayed features of accelerated ageing such as hair loss, reduced activ-
ity, shortened life expectancy, lordokyphosis (increased curvature of the
spine), and periophthalmic (around the eye) problems [43]. Littermates
that did not show a senescence-associated phenotype were also inbred
and senescence-resistant, longer-lived SAMR strains were obtained
such as SAMR1 (senescence accelerated mouse resistant 1). To better
delineate the role of speciﬁc single nucleotide variants (SNVs) of these
multigenic strains with distinct phenotypes, two recent independent
studies used whole exome sequencing to make the strains more useful
for studies into ageing and neurodegeneration [44,45].
In SAMP8 mice learning and memory deﬁcits were already evident
at 6 months of age and became more pronounced with advanced age
[46]. TAU was found to be hyperphosphorylated using a small set of
phosphorylation site-speciﬁc antibodies, but ﬁlament and NFT forma-
tion has not been reported indicating that the SAMP8 mice present
with an early rather than amore advanced TAU pathology [47]. Staining
with Aβ-speciﬁc antibodies suggested Aβ deposition [48,49], although,
because the murine protein differs from the human Aβ-precursor
protein (APP) and lacks the amino acids that are required to generate
Aβ, these deposits have been termed ‘Aβ-like’ [48]. Compared with
SAMR1 mice, age-related changes in cerebral energy production were
found in SAMP8 at 2 months followed by a decrease in mitochondrial
function [50,51]. More recent studies extended this ﬁnding by revealing
decreases in cytochrome C oxidase (COX) activity, mitochondrial ATP
content, and mitochondrial glutathione (GSH) levels in young SAMP8
compared with SAMR1 mice [52,53]. Ageing is accompanied not only
by increased mitochondrial ROS production due to ETC impairment
but also by an imbalance of the protective mitochondrial antioxidant
machinery. For instance, age-related changes in levels of antioxidant
enzymes, such as copper/zinc superoxide dismutase (Cu/Zn-SOD) and
manganese SOD (Mn-SOD) were found in the liver and cortex of
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Fig. 1. Themitochondrion under physiological and pathological conditions. Under healthy conditions, fusion andﬁssion are balanced, and damagedmitochondria are removed by a process
termedmitophagy. Both antero- and retrograde axonal transports are unimpaired providing the synapses with sufﬁcient numbers of functional mitochondria to meet the special energy
requirement and calcium buffering of this cellular compartment. Under conditions of elevated TAU, the delicate balance of ﬁssion and fusion is deregulated. Fission is impaired and an
elongatedmitochondrial network results. Thismay ormay not affect mitophagy. Phosphorylated TAU also impairs anterograde transport of distinct cargoes, which include mitochondria.
As a consequence, less mitochondria are provisioned to the synapses, which leads to synaptic degeneration. In the scheme, key molecules with roles in mitochondrial transport are indi-
cated, with kinesin being the actual motor andMiro and Milton being adaptor proteins. Inset: Elevated levels of phosphorylated TAU selectively impair complex I of the electron transfer
chain, ultimately resulting in reduced levels of ATP and hence, energy deprivation of affected neurons. Hyperphosphorylated forms of TAU also cause an increased production of reactive
oxygen species (ROS) and reduced activities of detoxifying enzymes (detox. enz.) including superoxide dismutase (SOD).
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creased lipid peroxidation and carbonyl damage is present as early
as two months of age [57]. Furthermore, SAMP8 mice reveal age-
dependent reductions of various receptors including the NMDA receptorthat has a role in excitotoxicity as discussed below [58]. Whereas SAMP
mice are certainly a better model for accelerated ageing rather than
neurodegeneration, they nonetheless support increased oxidative stress
as a keymechanism in the ageing process. Crossing TAU transgenicmice
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might establish a more advanced model of neurodegeneration com-
pared to one where the TAU transgene is expressed on a conventional
inbred background such as C57Bl/6.
2.3. The Harlequin model
Another, although less frequently, employed strain with mitochon-
drial dysfunction and oxidative stress is the Harlequin (Hq) mutant
mouse strain. Hq mice show an 80–90% depletion of the mitochondrial
apoptosis-inducing factor (AIF) resulting in reduced levels of complex I
of the ETC and increased oxidative stress [59]. Interestingly, although
AIF is reduced throughout the brain, neuronal loss is largely restricted
to distinct brain regions (cerebellum and retina), indicating selective
vulnerability. Because a mitochondrial dysfunction speciﬁcally of com-
plex I characterizes the P301L TAU transgenic pR5mice, the two strains
were crossed. This caused an increased TAU pathology (higher degree
of phosphorylation and more NFTs) and age-dependent cerebellar
neurodegeneration that was preceded by decreased activities of the
ETC and depletion of ATP levels [60]. Interestingly, low levels of TAU
in the cerebellar granule cell layer signiﬁcantly increased cerebellar ap-
optosis and led to an aggravation of motor deﬁcits even though only a
very small number of cerebellar granule neurons were positive for
TAU phospho-epitopes. This implies that in particularly vulnerable neu-
ronal populations such as the Hq cerebellar granule cells, even low
levels of non-hyperphosphorylated TAUmay be sufﬁcient to induce ap-
optosis and cause functional neurological impairment [60]. Analysis of
the activities of complexes I–V revealed a complex picture: In the
TAU/Hq mice an additive effect of the two mutations was observed,
i.e. both a reduced complex I protein content caused by the Hq mouse
mutation and a functional reduction of the remaining complex I activity
caused by additional TAU expression. For complex III, for example, early
decreases in activity were observed in 1-month-old TAU transgenic and
TAU/Hq mice. However, while TAU single mutant mice were able to
compensate for this deﬁciency, complex III activity remained reduced
in the TAU/Hq double mutant mice at 7 months. Together this study
demonstrates a mutual reinforcement of the TAU pathology and mito-
chondrial dysfunction in vivo, proposing TAU/Hq double mutant mice
as a valuable model to study TAU-related neurodegenerative changes
in a setting of impaired mitochondrial function.
3. TAU speciﬁcally impairs complex I and Aβ complex IV
3.1. Proteomic and functional studies in P301L TAU transgenic mice
An unbiased approach to address TAU-mediated impairment in
model systems is by functional genomics that generally generates long
lists of deregulated transcripts and proteins, which can then be grouped
by category analysis [61]. P301L TAU expressing pR5 mice reveal a sig-
niﬁcant aggregation of TAU at an early age, with NFTs developing
around the age of 6 months, and hence they represent a model suited
for the proteomic investigation of TAU-related changes in AD [62,63].
A mass spectrometric analysis of fractionated brain proteins derived
from these mice revealed mainly a deregulation of mitochondrial respi-
ratory chain complex components (including complex V), antioxidant
enzymes, and synaptic proteins [64]. The reduction in mitochondrial
complex V levels in the pR5 mice that was revealed using proteomics
was also conﬁrmed as decreased in brains from human carriers of the
P301L FTDP-17 mutation. The functional analysis demonstrated age-
related mitochondrial dysfunction, together with reduced NADH ubi-
quinone oxidoreductase (complex I) activity as well as age-related im-
paired mitochondrial respiration and ATP synthesis in the pR5 mouse
model. Mitochondrial dysfunction was further associated with higher
ROS levels in aged transgenic mice, concomitant with the upregulation
of antioxidant enzymes in response to oxidative stress (Fig. 1). In-
creased TAU pathology resulted also in lipid peroxidation [64]. Becauseprior studies had shown that Aβmainly impairs complex IV [65,66], the
ﬁnding that TAUmainly impairs complex I of the ETC demonstrated for
the ﬁrst time that TAU pathology also leads to metabolic impairment
and oxidative stress, by mechanisms that are distinct from those
exerted by Aβ. How TAU affects complex activities is not understood
and TAUmaywell do so indirectly. For Aβ, interactionwith and binding
to mitochondrial proteins (such as Aβ-binding alcohol dehydrogenase,
ABAD; or the voltage-dependent anion channel 1 protein, VDAC) has
been postulated [67,68]. Intracellular localization of Aβ has been
questioned by a recent study, however, which highlights the use of
antibodies in these studies that bind not only to Aβ but also to its
precursor protein, APP [69]. Because VDAC was found to interact with
phosphorylated TAU it has been proposed that phosphorylated TAU
may block mitochondrial pores and that one of TAU's functions is to
maintain normal mitochondrial pore opening and closure [68].
3.2. P301L TAU transgenic mice crossed with Aβ-forming mice
While the focus of this review article is on TAU and not on Aβ, it is
still worthwhile looking into models that combine both pathologies.
When the triple transgenic tripleAD mouse model (pR5/APPsw/PS2
N141I) was subjected to quantitative proteomics, this revealed that
one-third of the proteins had functions in mitochondria, speciﬁcally
complexes I and IV. Therefore, mitochondrial functions were assessed
[70]. Again, deregulation of the activity of complex I was found to be
TAU-dependent, and deregulation of complex IV Aβ-dependent, when
analyzing 10-month-old tripleAD mice. The convergent effects of Aβ
and TAU led to a depolarization of themitochondrial membrane poten-
tial in tripleAD mice already at the age of 8 months. Additionally, we
found that age-related oxidative stress played a signiﬁcant part in the
deleterious vicious cycle by exaggerating Aβ- and TAU-induced distur-
bances in the respiratory system and ATP synthesis, ﬁnally leading to
synaptic failure. Furthermore, synergistic effects of TAU andAβ onmito-
chondrial impairment were revealed.
These data complement those obtained in another triple transgenic
mouse model, 3xTg-AD (P301Ltau/APPSw/PS1 M146L) [71]. Mitochon-
drial dysfunctionwas evidenced by an age-related decrease in the activ-
ity of regulatory enzymes of the oxidative phosphorylation system such
as COX, or of the TCA cycle such as pyruvate dehydrogenase, analyzing
3xTg-AD mice between 3 and 12 months of age [72]. In addition,
these mice also exhibited increased oxidative stress and lipid pero-
xidation. Most of the effects on mitochondria were seen at the age of
9 months, whereas mitochondrial respiration was signiﬁcantly de-
creased at 12 months of age. Importantly, mitochondrial bioenergetic
deﬁcits were found to precede the development of AD pathology in
these mice. In a follow-up study, the 3xTg-AD mice were analyzed by
2D-DIGE, a quantitative proteomic proﬁling method [73]. Proteins that
were dysregulated in 3xTg-AD cortices functioned in a wide variety
of metabolic pathways, including the TCA cycle, oxidative phospho-
rylation, pyruvate metabolism, glycolysis, oxidative stress, fatty acid
oxidation, ketone body metabolism, ion transport, apoptosis, and mito-
chondrial protein synthesis. These alterations in themitochondrial pro-
teome of the cerebral cortices of 3xTg-ADmice occurredwell before the
development of signiﬁcant Aβ plaques and NFTs, supporting the notion
that mitochondrial dysregulation is an early event in AD pathogenesis.
4. TAU impairs mitochondrial transport
Mitochondria can move in both anterograde and retrograde direc-
tions in one axon [74]. Early studies in wild-type TAU overexpressing
mice using pulse-chase experiments had already revealed that TAUme-
diates impaired anterograde transport [75]. In K369I mutant TAU trans-
genic K3 mice, it was then demonstrated that elevated TAU impairs
transport of distinct cargoes including mitochondria, both in the
nigrostriatal pathway and in the sciatic nerve [28]. More speciﬁcally,
by ligating the sciatic nerve proteins whose transport was impaired
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impaired axonal transport. It was found that complex V accumulated
proximally and distally of the ligation in wild-type nerves, representing
bidirectional transport of mitochondria. In ligated transgenic nerves,
however, complex V accumulated only in the distal part, suggesting im-
paired anterograde and unaffected retrograde transports of mitochon-
dria in K3 mice (Fig. 1). As an underlying pathomechanism, trapping of
the kinesin adaptor molecule JIP1 by phosphorylated forms of TAU in
the soma was identiﬁed. This trapping prevented JIP1 from loading dis-
tinct cargoes (including mitochondria) onto the kinesin machinery for
transport down the axon. Relocalization of JIP1 from the axon to the
soma was also found in the AD brain underscoring the validity of the
ﬁnding in the transgenic model [76]. Another pathomechanism was
identiﬁed in the squid axon, where ﬁlamentous, but not soluble, forms
ofwild-type TAUwere found to inhibit anterograde transport by activat-
ing axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3
(GSK3), independent of microtubule binding [77]. In a related study, in-
creased expression of GSK3β and the p25 activator of cyclin dependent
kinase 5 (cdk5) in neurons was shown to cause an increased pausing
ofmitochondria rather than changes to their velocities [78]. Competition
for binding to kinesin has been suggested by co-immunoprecipitation
experiments: The data indicate that TAU being a cargo of kinesin itself
may displace other kinesin-based cargo, including cytoskeletal proteins
and organelles such as mitochondria [79]. Also in C. elegans, perturbed
axonal transport of mitochondria was reported when so-called pro-
aggregant tau was expressed which causes TAU aggregation [80].
While TAU is often treated as if it were one protein, it is in fact sev-
eral proteins. Differential effects of three-repeat (3R) and four-repeat
(4R) TAU on mitochondrial axonal transport have been reported [81].
As 3R TAU is believed to be less tightly associated with microtubules
than 4R TAU [82,83], it was postulated that 4R TAUmay lead to greater
alterations of organelle transport than 3R TAU. Indeed, while both 3R
and 4R TAU changed the normal mitochondrial distribution within the
cell body and reduced mitochondrial localization to axons, the effects
of 4R TAU were more pronounced. Furthermore, 3R and 4R TAU caused
different alterations in retrograde and anterograde transport dynamics;
however, 3R TAU had a slightly stronger effect on axon transport dy-
namics. TAU over-expression in general increased the net movement
of axonal mitochondria towards the neuronal cell body [81]. Multiple
studies have shown that Aβ, the second key player in AD, impairs mito-
chondrial transport [84], while a recent study using oligomeric Aβ did
not ﬁnd changes to mitochondrial motility [85]. However, reducing
TAU levels prevents Aβ toxicity as discussed below, andmore speciﬁcally
the defects in axonal transport induced by Aβ in APP mutant mice [86].
More recently, RNAi-mediated knockdown ofMilton orMiro, which
encodes adaptor proteins essential for axonal transport of mitochon-
dria, in human TAU transgenic ﬂies was found to enhance the TAU-
induced neurodegeneration [87] (Fig. 1). Phosphorylation of TAU at
the 12E8 phospho-epitope Ser262 was increased when Milton or Miro
was reduced. Partitioning defective-1 (PAR-1), the Drosophila homolog
of mammalian microtubule afﬁnity-regulating kinase (MARK) mediat-
ed this increase. Mutagenesis studies suggested that increased phos-
phorylation of the 12E8 epitope through PAR-1 contributes to TAU-
mediated neurodegeneration in a pathological context when axonal
mitochondria are depleted. Mitochondrial movement in the neuritic
processes of PC12 cells was inhibited when another phospho-epitope
of TAU, AT8 (comprised of three sites, Ser199, Ser202, and Thr205)
was changed to phosphomimetic aspartates [88]. These mutations also
caused an expansion of the space between microtubules in cultured
cells when membrane tension was reduced by disrupting actin ﬁla-
ments. Thus, the authors concluded that TAU phosphorylation at the
AT8 sites may affect mitochondrial movement by controlling microtu-
bule spacing [88]. In human embryonic stem cell-derived neural stem
cells the consequences of an overexpression of the longest human tau
isoform, 2N4R tau versus pseudohyperphosphorylated tau (p-tau) was
studied. Interestingly, p-tau, but not 2N4R tau, readily leads to TAUaggregation and impaired mitochondrial transport in human neurons.
Although these alterations did not induce cell death, p-tau-expressing
neurons cultured under non-redox-protected conditions underwent a
pronounced degeneration with the formation of axonal varicosities se-
questering transported proteins and progressive neuronal cell death
[89]. That tau can impair axonal transport of mitochondria in the ab-
sence of hyperphosphorylation has been shown in P301L tau knock-in
mice that did not develop a TAU pathology. In fact, the overall phos-
phorylation of tau in these mice was reduced (e.g., at epitopes PHF-1
or AT270), perhaps due to a reduced microtubule binding [90]. The im-
pact of impaired transport on TAU pathology has also been studied. In
mice lacking the kinesin light chain 1 (KLC1) subunit of the anterograde
motor kinesin-1, this caused an axonopathy, with dystrophic axons
exhibiting abnormal tau hyperphosphorylation and accumulation [91].
Together these studies illustrate that phosphorylated forms of TAU
alter mitochondrial transport.
5. TAU impairs mitochondrial dynamics
Mitochondria differ remarkably from each other in size depending
on cell-type and subcellular compartment [92,93]. Because axons and
dendrites have differential energy demands, themitochondrial network
is generally more elongated in the cell body and dendrites of a neuron,
and more fragmented in the axon [94,95] (Fig. 1). Moreover, a distinc-
tion is made between nonsynaptic and synaptic mitochondria [96–98].
To meet the speciﬁc subcellular demands, the mitochondrial network
is shaped by a set of proteins that regulates fusion and ﬁssion [99]. In
mammalian cells three large GTPases govern fusion: Mitofusins 1 and
2 (MFN1 and MFN2) dimerize on the outer membranes of adjacent mi-
tochondria to induce outer membrane fusion. This is followed by fusion
of the inner membranes, a process mediated by OPA1 (optic atrophy 1)
that resides in the intermembrane space [100,101]. Fission is under
control of yet another GTPase, DRP1 (dynamin-related protein 1, also
known as DLP1 andDNM1) [102]. A set of additional proteins, including
FIS1, mitochondrial ﬁssion factor (MFF), and mitochondrial dynamics
proteins of 49 and 51 kDa (MiD49 andMiD51), have a role in recruiting
and assembling DRP1 at the outer membrane [103]. Fission and fusion
need to be balanced. For example, knockdown of Drp1 leads to mito-
chondrial elongation, respiratory dysfunction and, ultimately, apoptosis
[104], whereas elevatedmitochondrial fusion is also a stress response in
certain situations, enhancing ATP production and resistance to apopto-
sis [105], as reviewed recently [99].
Not surprisingly, an impaired balance of ﬁssion and fusion has been
reported in AD, both at the transcript and protein levels [106,107]. Re-
duced levels of DRP1 and increased mitochondrial length were found
in one study [108], whereas another revealed reduced cytoplasmic
levels but (although not statistically signiﬁcant) increasedmitochondri-
al levels of DRP1, indicative of increased ﬁssion [106,109]. This and
other recent studies suggest some degree of variability in the regulation
of mitochondrial dynamics. For a conclusive picture it will be crucial to
analyze the subcellular localization and post-translationalmodiﬁcations
of DRP1, rather than global changes.
Mitochondrial dynamics has also been studied in mouse models of
AD. Here, a signiﬁcant body of data is available for the role of Aβ,
which overall suggests that its net effect is towards increased fragmen-
tation [106,108,110,111]. However, as discussed above, in addition to
Aβ, TAU also forms aggregates in the AD brain and it would not be sur-
prising if the observed differences in the impairment of complex activ-
ities would also extend to differences in the rates of ﬁssion and fusion.
While hyperphosphorylation of TAU is believed to be a precipitating
event in disease, recent data suggest that carboxy-terminal cleavage of
TAU, which impairs mitochondrial function may also be critical
[112,113]. Full-length TAU induced an increase in mitochondrial size,
whereas truncated TAU induced mitochondrial fragmentation [114]. In
neuroblastoma cells, P301L TAU impaired mitochondrial motility, to-
gether with a down-regulation of both ﬁssion and fusion [115]. When
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enhanced oxidative stress, and caused a depletion of the mitochondrial
membrane potential in cortical neurons. These effects were eithermod-
est or absentwhen Aβwas combinedwith full-length TAU, suggesting a
speciﬁc synergistic cooperation of cleaved TAU with Aβ in disrupting
mitochondria [112,113]. An altered distribution of mitochondria, with-
out a change in size, was found in transgenic mice with high levels of
P301L mutant TAU expression [116]. In these mice, mitochondrial dis-
tribution was progressively disrupted with age, particularly in somata
and neurites that contained TAU aggregates. Apparently, the effects of
TAU on mitochondria, both independently and in cooperation with
Aβ, varywidely between TAU species, although the reasons for these di-
vergent effects remain to be determined.
New light on TAU's role in mitochondrial dynamics was shed by a
complementary study in TAU transgenic worms and ﬂies. It has previ-
ously been found that TAU induces the stabilization and bundling of ﬁl-
amentous (F)-actin [117]. Because localization of the ﬁssion protein
DRP1 to mitochondria is an actin-dependent process, whereby DRP1
and mitochondria (via myosin II) must interact with ﬁlamentous (F)-
actin prior to their colocalization, increased F-actin in humanTAU trans-
genic mice and ﬂies disrupts the physical association of mitochondria
and DRP1, leading to mitochondrial elongation [118,119] (Fig. 1). This
causes neurotoxicity that can be rescued by reducing mitochondrial fu-
sion, enhancing ﬁssion, or reversing actin stabilization. The study fur-
ther found that elongation is not a secondary effect of impaired axonal
transport [118]. Despite those new highlights on the role of TAU in the
impairment of mitochondrial dynamics, there is no clear evidence of
its role in mitochondrial turnover. In fact, as mentioned above, fusion/
ﬁssion activity plays an important role in mitochondrial quality control.
It allows the exchange of materials such as lipids, proteins, metabolites
and mtDNA throughout the mitochondrial network, avoiding energetic
deﬁciencies. However, when mitochondria are extensively damaged,
they exit the fusion/ﬁssion cycle and are selectively eliminated by
mitophagy (Fig. 1). This process occurs when mitochondria are in a
fragmented state andwhen themitochondrial membrane is depolarized
after stress [120]. Mitochondria are degraded by engulfment into
autophagosomes, which fuse with lysosomes and break down the or-
ganelles. In the case where the process of mitophagy is disturbed, a
decreased cellular respiration has been observed, parallel to an accumu-
lation of oxidized proteins [33]. Nothing seems to be known about the
effect of TAU on mitochondrial turn-over but since new evidence
shows that TAU may lead to mitochondrial elongation (fused state),
we can speculate that it might decrease the elimination of damagedmi-
tochondria via the process of mitophagy (which requires mitochondrial
fragmentation). However, because AD is characterized by both TAU and
Aβ pathology, future studies into mitochondrial dynamics/mitophagy
need to take both molecules into consideration. More speciﬁcally, it
will be necessary to ﬁrstly analyze synaptosomal as well as total mito-
chondria, and secondly, human tissue that represents the full spectrum
of TAU and/or Aβ pathology, to dissect effects of Aβ onmitochondria dy-
namics from those of TAU.
6. TAU mediates excitotoxicity
TAU affectsmitochondrial dysfunction also because of its crucial role
inmediating excitotoxicity, a pathomechanism that has been implicated
in AD [121]. Under basal conditions, mild activation of theNMDA recep-
tor (NMDAR) results in physiological ROS production, while under neu-
rodegenerative conditions triggered by Aβ, over-activation of NMDARs
causes excessive calcium inﬂux, nitric oxide (NO) activation, mitochon-
drial depolarization and superoxide formation that result in neuronal
damage and death [122–124]. Aβ is believed to exert excitotoxicity ei-
ther directly or indirectly, by over-activating the NMDAR [125]. NO ex-
erts themajority of its effects by reacting with a cysteine thiol on target
proteins, a process termed S-nitrosylation. This modiﬁes enzymes with
a role in glycolysis, gluconeogenesis and oxidative phosphorylation,indicating that this type of posttranslational modiﬁcation may regulate
metabolism and mitochondrial bioenergetics [126]. In a recent study,
inhibition of Drp1 was found to prevent excitotoxic cell death in a hip-
pocampal cell culture system [127]. Calcium inﬂux also stimulates ki-
nases, causing TAU to detach from microtubules and relocalize to the
somatodendritic domain, where it aberrantly interacts with proteins in-
cluding JIP1, thereby impairing mitochondrial transport [28].
Is there a more direct role for TAU in excitotoxicity? In a patho-
cascade, Aβ has been placed upstream of TAU [128]. This concept has
been proven in P301L mutant TAU transgenic mice that develop an in-
creased number of NFTs, either by crossing them with Aβ plaque-
forming transgenic mice [129], or by intracerebral injections of Aβ
[130]. While Aβ causes TAU aggregation, its toxicity is also dependent
on TAU as has been ﬁrst shown in vitro [131] and subsequently
in vivo [132]. Removing TAU largely abrogates the pathological features
that characterize Aβ plaque-formingmice, namely prematuremortality,
high susceptibility to experimentally induced excitotoxic seizures and
memory deﬁcits [132]. Mechanistically, this protection appeared to be
conferred by a reduced susceptibility to excitotoxicity either when
TAU was absent or when its levels were reduced [132,133]. Even
under physiological conditions, TAUwas found to be present in the den-
drite (although at low quantities compared with the axon), where it is
critically involved in postsynaptic NMDAR downstream signalling by lo-
calizing the SRC kinase FYN to the dendrite. FYN phosphorylates the
NMDAR that then recruits the postsynaptic scaffolding protein PSD-95
to form a complex [133]. The TAU axis hypothesis claims that as TAU ac-
cumulates in a phosphorylated form in the dendrite, it mediates the
toxic effects of Aβ by causing increased concentrations of FYN which is
then available to phosphorylate the excitotoxic NMDAR signalling com-
plex [134]. Aβ, Fyn and TAU therefore seem to orchestrate neuronal
damage [133,135,136]. It has been shown that synaptic NMDAR signal-
ling and extrasynaptic NMDAR signalling have opposite effects on cell
survival and that differentially located NMDARs are coupled to different
intracellular cascades. A recent study found that Aβ induces dendritic
spine loss via a pathway involving synaptic NR2A-containing NMDARs
whereas activation of extrasynaptic NR2B-containing NMDARs is re-
quired for neurodegeneration that is TAU-dependent [137]. Together
this suggests thatmanipulating components of theNMDAR or the inter-
action of TAU and FYN may be therapeutically beneﬁcial. In fact,
disrupting the complex between NMDAR and PSD-95 pharmacological-
ly was found to protect Aβ plaque-formingmice from premature death,
memory impairment and the susceptibility to excitotoxic seizures [133].
In conclusion, TAU affects mitochondrial dysfunction also because of its
crucial role in mediating excitotoxicity, a pathomechanism that has
been implicated in AD.
7. Integration—mitochondria are key targets of Aβ and TAU toxicity
in AD
Mitochondria are key targets of Aβ and TAU toxicity in AD (Fig. 1). A
picture is emerging whereby these two molecules damage mitochon-
dria in multiple ways, by marching separately and striking together.
While the causes of sporadic AD are not known it is evident that Aβ
and TAU levels are elevated at an early stage. An impaired homeostasis
because of increased Aβ production and decreased clearance causes in-
creased levels, which acts on mitochondria by impairing complex IV
function, and by facilitating the fragmentation of mitochondria. Both in-
sults cause increases in ROS levels, decreased activities of detoxifying
enzymes such as superoxide dismutase (SOD), and an impaired mito-
chondrial membrane potential that results in reduced ATP levels. Ele-
vated Aβ levels also result in the overexcitation of neurons, which
leads to an inﬂux of calcium ions, with the consequence of increased
COX levels, which then damages mitochondria. When Aβ levels are
increased this also activates distinct TAU kinases and/or inactivates
TAU phosphatases resulting in a massive hyperphosphorylation of
TAU. Hyperphosphorylated TAU speciﬁcally impairs complex I of the
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lipid peroxidation, decreased activities of detoxifying enzymes such as
superoxide dismutase (SOD), and an impaired mitochondrial mem-
brane potential. It also impairs anterograde transport of mitochondria
and other cargoes by trapping the kinesin adaptor molecule JIP1 in the
neuronal cell body, preventing it from executing its normal function.
In AD, hyperphosphorylated TAU not only accumulates in the axon,
but also relocalizes and accumulates in the cell body and dendrites of af-
fected neurons. In the dendritic compartment, it facilitates the toxic ef-
fects of Aβ that are mediated by the NMDAR. Elevated levels of TAU
have also functional consequences on mitochondrial dynamics. TAU
causes actin stress ﬁbres to form. This blocks the proper execution of
DRP1-mediated ﬁssion with a net result of mitochondrial elongation.
This, similar to an augmented fragmentation caused by Aβ, causes in-
creased ROS levels, decreased activities of detoxifying enzymes and an
impaired mitochondrial membrane potential. In light of the apparently
opposing effects Aβ has on mitochondrial size it seems that either too
little or too much ﬁssion/fusion is detrimental for neurons. Obviously,
with TAU impairing axonal transport of mitochondria, the calcium buff-
ering requirements at the synapse are undermined. Together, TAU and
Aβ establish a vicious cycle of misregulated dynamics and transport of
the mitochondria, which together with alterations in mitochondrial
components such as complex proteins or mtDNA, causes mitochondrial
impairment in AD.
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